Pfizer says Phase 3 trials show LITFULO improves repigmentation at Week 52
PFE•Pfizer said Phase 3 trials showed LITFULO improved facial and overall skin repigmentation in patients with nonsegmental vitiligo versus placebo at Week 52. The company plans regulatory submissions to the FDA and EMA.
1. Trial results
Pfizer presented Phase 3 results showing LITFULO improved facial and overall skin repigmentation in patients with nonsegmental vitiligo versus placebo. Benefits continued to build from mid-study through Week 52.
2. Safety and submissions
Pfizer said the drug’s safety matched its established profile in alopecia areata, with no new safety signals reported in the vitiligo program. The company plans to submit the treatment to the FDA and EMA.
